{
  "docId": "019de075-7d9e-72c3-b72b-f46b67767727",
  "docSlug": "53c1bfc711678d7524a7d4316a5473e9",
  "documentTitle": "Chimerix | Investor Presentation Deck | 43 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 43,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "other",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a process flow diagram to illustrate the trial structure.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-7d9e-72c3-b72b-f46b67767727/17",
  "deckHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727",
  "deckJsonHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727.json",
  "deckAnchorHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.625,
        "w": 0.956,
        "x": 0.022,
        "y": 0.285
      },
      "kind": "diagram",
      "text": "Key Patient Inclusion -> Treatment -> Endpoints",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a86f2b3f-c797-452f-95d2-a3c6988d3a90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.408,
        "w": 0.35,
        "x": 0.022,
        "y": 0.398
      },
      "kind": "list",
      "text": "H3 K27M-mutant diffuse glioma; Radiation therapy recently completed; KPS >= 70 at time of randomization; Stable steroid dose; No prior bevacizumab; No temozolomide within three weeks",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a20bfe80-978d-4dac-9918-71a32a7d85de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.283,
        "w": 0.271,
        "x": 0.707,
        "y": 0.43
      },
      "kind": "list",
      "text": "Primary: Overall Survival; PFS (alpha-allocated); Secondary: steroid response, performance status, QoL, neurologic function",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2eaf88f-3e99-46ce-ab02-2003f5cef695",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.872,
        "x": 0.064,
        "y": 0.143
      },
      "kind": "paragraph",
      "text": "Now enrolling, a randomized, double-blind, placebo-controlled, multicenter international study in 450 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M-mutation.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a876bd7-faf4-42c8-8f76-2a85e596fc11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.163,
        "x": 0.105,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Excludes DIPG and spinal tumors",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "507ccc94-e33f-44f7-be97-f51d5e8a7fe9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.424,
        "x": 0.288,
        "y": 0.068
      },
      "kind": "title",
      "text": "Pivotal Phase 3 ACTION trial design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0070ab8-ba24-4fad-986c-00820b6c4a0f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a6cad647-3eac-4a6f-ad5b-7cf8a032e7c5",
      "evidence": "The slide contains a list of bullet points describing the Pivotal Phase 3 ACTION trial design.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "8db54612-f422-4474-8bb6-26ebd098bf2a",
      "evidence": "Flowchart showing patient inclusion leading to treatment arms and endpoints",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 43,
      "from": 16,
      "beatId": "159a3ef0-298f-499a-afc1-676405bbdbe9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents ONC201 as a solution, including its mechanism of action, market opportunity, and development plans",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 43,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "cb576a48-1f93-4d7c-8d9b-075787961712",
      "evidence": "The deck presents ONC201's potential for efficacy and market opportunity",
      "position": 1,
      "objective": "Can ONC201 be a quick win and a big bet for Chimerix?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}